ACR Meeting Abstracts

ACR Meeting Abstracts

  • Home
  • Meetings Archive
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018 ACR/ARHP Annual Meeting
    • 2017-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • Meeting Resource Center

Abstract Number: 0722

Myostatin in Idiopathic Inflammatory Myopathies: Seric Assessment and Disease Activity

Alexandrine Mahoudeau1, Céline Anquetil2, Nozomu Tawara1, Hossein Khademian1, Damien Amelin1, Yves Allenbach3 and Olivier Benveniste3, 1Center of Research in Myology, Sorbonne University, Paris, France, 2Center of Research in Myology, Sorbonne University - AP-HP, Pitié-Salpêtrière Hospital, Department of Clinical Immunology and Internal Medicine, Paris, France, 3Sorbonne University - AP-HP, Pitié-Salpêtrière Hospital, Department of Clinical Immunology and Internal Medicine, Paris, France

Meeting: ACR Convergence 2021

Keywords: cytokines, Disease Activity, Myositis

  • Tweet
  • Email
  • Print
Session Information

Date: Sunday, November 7, 2021

Session Title: Muscle Biology, Myositis & Myopathies Poster (0683–0722)

Session Type: Poster Session B

Session Time: 8:30AM-10:30AM

Background/Purpose: In Idiopathic Inflammatory Myopathies (IIM) disease activity is very difficult to assess and IIM may induce severe muscle damage, especially in immune-mediated necrotizing myopathies (IMNM). We hypothesize that myostatin, a negative regulator of muscle mass, could be a new biomarker of disease activity and/or muscle damage.

Methods: Prospective assessment of myostatin protein level in 447 IIM sera samples (dermatomyositis (DM), n=157; inclusion body myositis (IBM), n=72; immune-mediated necrotizing myopathies, n=125; anti-synthetase syndrome (ASyS), n=93) and 59 healthy donors (HD) was performed by ELISA. A gene transcript analysis was also carried out on 18 IIM muscle biopsies and 6 HD to analyze the expression of myostatin and myostatin pathway genes.

Results: IIM patients had lower myostatin circulating protein levels and gene expression compared to HD (2379 [1490; 3678] pg/ml vs 4281 [3169; 5787] pg/ml; p< 0.0001 and log2FC=-1.83; p=0.0005 respectively) (Fig1). Myostatin-related genes expression varied accordingly. Myostatin circulating levels were then assessed for each subgroups. Myostatin levels were lower in ASyS (3109 [1952; 4258] pg/ml; p=0,001), DM (2327 [1431; 3446] pg/ml; p< 0.0001), IMNM (2285 [1371; 3851] pg/ml; p< 0.0001) and IBM (2005 [1449; 2803] pg/ml; p< 0.0001) compared to HD (4281 [3169; 5787] pg/ml) (Fig2). Based on the Physician Global Activity score, inactive IIM patients had higher myostatin levels than active ones. This was the case for all IIM subgroups, except IMNM patients where low myostatin levels were maintained (2186 [1235; 3815] vs 2349 [1518; 3922] pg/ml; p=0.4) even during remission (Fig3).

Conclusion: Myostatin protein and RNA levels are decreased in all IIM patients and circulating protein levels are correlated with disease activity. Inactive ASyS and DM patients have higher level of myostatin than active patients. Myostatin could be a marker of disease activity in these two subgroups. However, IMNM patients do not have a significant increase in myostatin levels after disease remission. This observation may highlight a new pathological disease mechanism in IMNM patients.

Figure 1 : Quantification of circulating myostatin (A) and expression (Log2FC) of genes implicated in the myostatin pathway in IIM (B) compared to HD

FST: follisatin, MYOG: myogenin, MYF5: myogenic factor 5, INHBA: inhibin A, DCN: decorin, TRIM63: Tripartite Motif Containing 63, FBXO32: F-box Protein 32, MSTN: myostatin

Figure 2 : Circulating myostatin levels in IIM subgroups

Figure 3 : Circulating myostatin levels in active vs inactive IIM patients


Disclosures: A. Mahoudeau, None; C. Anquetil, None; N. Tawara, None; H. Khademian, None; D. Amelin, None; Y. Allenbach, None; O. Benveniste, None.

To cite this abstract in AMA style:

Mahoudeau A, Anquetil C, Tawara N, Khademian H, Amelin D, Allenbach Y, Benveniste O. Myostatin in Idiopathic Inflammatory Myopathies: Seric Assessment and Disease Activity [abstract]. Arthritis Rheumatol. 2021; 73 (suppl 9). https://acrabstracts.org/abstract/myostatin-in-idiopathic-inflammatory-myopathies-seric-assessment-and-disease-activity/. Accessed January 27, 2023.
  • Tweet
  • Email
  • Print

« Back to ACR Convergence 2021

ACR Meeting Abstracts - https://acrabstracts.org/abstract/myostatin-in-idiopathic-inflammatory-myopathies-seric-assessment-and-disease-activity/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

ACR Pediatric Rheumatology Symposium 2020

© COPYRIGHT 2023 AMERICAN COLLEGE OF RHEUMATOLOGY

Wiley

  • Home
  • Meetings Archive
  • Advanced Search
  • Meeting Resource Center
  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences